Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 7,413 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tissue specimen Clear all

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Forceps; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation
Interventions: Numeris-AF Tethered Coagulation System with VisiTrax; Device
Lead sponsor: nContact Surgical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Venice, Florida • Memphis, Tennessee

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gingival Recession
Interventions: CelTx, Autologous sub-epithelial connective tissue graft; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Implant Complication
Interventions: Vertical soft tissue augmentation; Procedure
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 18 Years to 99 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Female Infertility
Interventions: Ovarian tissue transplant; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Nasal Obstruction
Interventions: Vivaer Stylus; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Fresno, California • Colorado Springs, Colorado • Oradell, New Jersey + 6 more

Conditions: Breast Cancer Female
Interventions: Bupivacaine Hydrochloride, Placebo Drug, Pulsed Electromagnetic Field (PEMF) Device, Placebo Device, Ropivacaine Hydrochloride; Drug · Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Keratitis
Interventions: Acthar; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Glendale, California • Newport Beach, California + 6 more

Conditions: Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)
Interventions: Tumor core biopsy for RNA isolation; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Cystic Fibrosis
Interventions: Ethambutol, Rifampin, Azithromycin, Pancrelipase; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Human Immunodeficiency Virus
Interventions: flexible sigmoidoscopy or colonoscopy with biopsies; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 10 Years to 21 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions: Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 698
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more

Conditions: Obesity, Exercise
Interventions: exercise; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 21 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Breast Cancer
Interventions: filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody m170; Biological · Drug · Procedure + 1 more
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Insulin Resistance, Postmenopause
Interventions: metformin, leuprolide injection, placebo pill, placebo injection; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years to 79 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Laryngeal Diseases
Interventions: CO2 laser; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 88 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ixabepilone; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Incisional Hernia
Interventions: dHACM (AmnioWrap); Biological
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 533 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Healthy Volunteers
Interventions: Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron; Drug · Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma, Stage I Breast Carcinoma, Stage II Breast Carcinoma
Interventions: Intraoperative Radiotherapy; Procedure
Lead sponsor: St. Joseph Hospital of Orange; Other
Eligibility: 41 Years to 90 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Orange, California

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study of Forceps Cannulation During ERCP

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage

Vertical Soft Tissue Augmentation With CTG vs ADM

Autologous Ovarian Tissue Transplantation

Treatment of Nasal Airway Obstruction Using the Aerin Medical Device

PEMF and PEC Blocks in Mastectomy Reconstruction Patients

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Exercise Training and Insulin Sensitivity

Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Insulin Resistance and Testosterone in Women

Comparison of Office-based KTP and CO2 Laser Outcomes in Patients With Vocal Cord Lesions.

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

A Prospective, Double-Blinded, Randomized Controlled Trial of dHACM for Incisional Hernia Prophylaxis

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Single Fraction Intraoperative Radiotherapy

Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer